August 28, 2014 9:51 AM ET


Company Overview of Naurex, Inc.

Company Overview

Naurex, Inc., a clinical-stage company, develops novel therapies for psychiatry and neurology disorders for modulating the N-methyl-D-aspartic acid receptor (NMDAR). It offers novel chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The company provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. It offers its products for central nervous system conditions, including depression, anxiety disorders, cognitive disorders, pain, and addiction. Naurex, Inc. was founded in 2006 and is based in Evanston, Illinois.

1801 Maple Avenue

Suite 4300

Evanston, IL 60201

United States

Founded in 2006



Key Executives for Naurex, Inc.

Chief Executive Officer
Age: 56
Executive Chairman
Age: 76
Chief Medical Officer
Age: 59
Chief Scientific Advisor
Compensation as of Fiscal Year 2014.

Naurex, Inc. Key Developments

Naurex, Inc. Presents at Boston CEO Conference, Jun-05-2014 01:00 PM

Naurex, Inc. Presents at Boston CEO Conference, Jun-05-2014 01:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Derek A. Small, Director.

Naurex Inc. Reports Positive Phase 2b Results for Novel Antidepressant GLYX-13 and Advances NRX-1074 into Phase 2 Depression Study

Naurex Inc. announced that its two lead antidepressant programs achieved major milestones. Results from a Phase 2b clinical study of the company's lead compound, GLYX-13, showed that the drug was well-tolerated and that the rapid, robust, and sustained antidepressant effects observed in an earlier single-dose study were achieved and maintained with repeat dosing in subjects with difficult-to-treat depression. The company also reported that it initiated a Phase 2a study of its second-generation, orally active agent, NRX-1074, based on positive results from a recently completed Phase 1 study. NRX-1074 is in development for major depressive disorder (MDD). The Phase 2b GLYX-13 study was conducted across 25 U.S. sites that enrolled more than 400 subjects with MDD who had an inadequate response to their current antidepressants. The top-line results confirmed that repeat dosing of GLYX-13 resulted in the maintenance of marked and clinically meaningful antidepressant effects. No drug-related serious adverse events were reported, no subjects dropped out of the study due to drug-related adverse events, and there were no signs of the psychotomimetic side effects associated with NMDA receptor antagonists, such as ketamine. The objectives of the Phase 2a study now underway for NRX-1074 are to evaluate the safety and efficacy of a single dose of the compound administered to subjects with MDD. NRX-1074 is considerably more potent than GLYX-13 and, in preclinical studies, it has shown activity similar to GLYX-13, including signs of rapid onset and long-acting duration of antidepressant-like effect. The Phase 2a study of NRX-1074 follows successful completion of a randomized, placebo-controlled Phase 1 study in which NRX-1074 was well-tolerated by normal volunteers.

Naurex, Inc. Presents at UBS Global Healthcare Conference, May-19-2014 01:00 PM

Naurex, Inc. Presents at UBS Global Healthcare Conference, May-19-2014 01:00 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Norbert G. Riedel, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Emergent Manufacturing Operations Meriden, LLC United States
ALTANA Pharma US, Inc. United States
Amneal Pharmaceuticals, L.L.C. United States
FluGen, Inc. United States
FLAVORx, Inc. United States

Recent Private Companies Transactions

Private Placement
May 1, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Naurex, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at